Scarica l'app Stockscreener
12.02
0.66%
-0.08
Dopo l'orario di chiusura:
11.80
-0.22
-1.83%
Precedente Chiudi:
$12.10
Aprire:
$12.11
Volume 24 ore:
1.71M
Relative Volume:
1.05
Capitalizzazione di mercato:
$1.24B
Reddito:
-
Utile/perdita netta:
$-135.21M
Rapporto P/E:
-8.3991
EPS:
-1.4311
Flusso di cassa netto:
$-114.35M
1 W Prestazione:
+15.36%
1M Prestazione:
+26.13%
6M Prestazione:
-0.74%
1 anno Prestazione:
+5.07%
Intervallo 1D:
$11.92
$12.57
Intervallo di 1 settimana:
$10.37
$12.57
Portata 52W:
$7.23
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Nome
Oric Pharmaceuticals Inc
Settore
Industria
Telefono
(650) 388-5600
Indirizzo
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
12.02 | 1.25B | 0 | -135.21M | -114.35M | -1.4311 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-06-12 | Ripresa | Stifel | Buy |
| 2026-05-15 | Aggiornamento | Goldman | Neutral → Buy |
| 2026-01-07 | Iniziato | Piper Sandler | Overweight |
| 2025-11-20 | Iniziato | Evercore ISI | Outperform |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-09-04 | Ripresa | Guggenheim | Buy |
| 2025-07-08 | Iniziato | Ladenburg Thalmann | Buy |
| 2024-10-31 | Iniziato | Wells Fargo | Overweight |
| 2024-09-06 | Iniziato | Stifel | Buy |
| 2024-02-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-09-22 | Iniziato | Wedbush | Outperform |
| 2023-03-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-16 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-18 | Ripresa | Oppenheimer | Perform |
| 2022-04-04 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-03-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-03-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-07-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-01-25 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-13 | Iniziato | Robert W. Baird | Outperform |
| 2020-08-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-08-03 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-19 | Iniziato | Citigroup | Neutral |
| 2020-05-19 | Iniziato | Guggenheim | Buy |
| 2020-05-19 | Iniziato | JP Morgan | Overweight |
| 2020-05-19 | Iniziato | Jefferies | Buy |
Mostra tutto
Oric Pharmaceuticals Inc Borsa (ORIC) Ultime notizie
Oric Pharmaceuticals Inc (ORIC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Oric Pharmaceuticals Inc (ORIC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Orbimed Advisors LLC Reduces Stock Holdings in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
ORIC|Oric Pharmaceuticals Inc|Price:12.100|Chg%:+1.210 - TradingKey
Oric Pharmaceuticals Inc (ORIC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Oric Pharmaceuticals Inc (ORIC) Institutional Confidence - TradingKey
Oric Pharmaceuticals Inc (ORIC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oric Pharmaceuticals Inc (ORIC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oric Pharmaceuticals (NASDAQ:ORIC) Upgraded at Wall Street Zen - MarketBeat
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Up 5.4%Time to Buy? - MarketBeat
Siren L.L.C. Has $37.99 Million Holdings in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Oric Pharmaceuticals (ORIC) Stock Analysis: A Biotech Gem With An 86% Upside Potential - DirectorsTalk Interviews
ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses - Stocktwits
ORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen Bull Case (NASDAQ:ORIC) - Seeking Alpha
Oric Pharmaceuticals stock trades down to 10.69 as oricpharma promotes BTIG conference meeting - Traders Union
Discipline and Rules-Based Execution in ORIC Response - Stock Traders Daily
ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 - The Manila Times
ORIC® Pharmaceuticals Announces Three Presentations at the - GlobeNewswire
Oric Pharmaceuticals (ORIC) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
How ORIC’s Global Phase 3 Rinzimetostat Trial with Bayer’s NUBEQA Has Changed Its Investment Story (ORIC) - Sahm
ORIC Launches Phase 3 Himalayas-1 Trial - t.co
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer - Sahm
Oric Pharmaceuticals (ORIC) Launches Phase 3 Trial for Prostate Cancer Treatment - GuruFocus
ORIC Pharmaceuticals initiates phase 3 prostate cancer trial - Investing.com
ORIC Pharmaceuticals initiates phase 3 prostate cancer trial By Investing.com - Investing.com India
Bayer Will Provide NUBEQA at No Cost for ORIC’s Global Trial - Stock Titan
Y Intercept Hong Kong Ltd Sells 229,431 Shares of Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Oric Pharmaceuticals director Heyman sells $3,600 in stock - Investing.com
Form 4 Oric Pharmaceuticals Inc For: 8 July By Investing.com - Investing.com South Africa
Oric Pharmaceuticals director Heyman sells $3,600 in stock By Investing.com - Investing.com India
Oric Pharmaceuticals (ORIC) entity sells 300 shares under 10b5-1 plan - Stock Titan
Price to sales forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView
ORIC focuses on oncology pipeline as Oric Pharmaceuticals positions for long-term growth - Ad Hoc News
Price to sales forward of Oric Pharmaceuticals, Inc. – DUS:4TZ - TradingView
Form 144 Oric Pharmaceuticals For: 6 July By Investing.com - Investing.com Nigeria
ORIC (NASDAQ) Form 144: Affiliate notifies sale of 7,000 Common shares via J.P. Morgan - Stock Titan
[144] Oric Pharmaceuticals, Inc. SEC Filing - Stock Titan
ORIC Pharmaceuticals Slips 2.49% as Stock Tests Key Support LevelsBreakout Stock Alerts - DonanımHaber
Oric Pharmaceuticals stock extends rally with bullish signals after 22 percent weekly surge - Traders Union
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ORIC awards new hires 44,400 stock options and 7,200 RSUs - Stock Titan
ORIC Pharmaceuticals grants stock options and r... - Pluang
Wedbush reiterates ORIC Pharmaceuticals (ORIC) outperform recommendation - MSN
Enterprise value to EBITDA forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView
Price to earnings forward of Oric Pharmaceuticals, Inc. – FWB:4TZ - TradingView
Price to book forward of Oric Pharmaceuticals, Inc. – FWB:4TZ - TradingView
Enterprise value to revenue forward of Oric Pharmaceuticals, Inc. – FWB:4TZ - TradingView
Enterprise value to EBIT forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView
Oric Pharmaceuticals Inc Azioni (ORIC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):